Építés alatt – nem éles oldal
Belépés
Leállítva2/3. fázis

STRIDES - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia

A legfontosabb adatok

Ki végzi
Seelos Therapeutics, Inc.
Hol
Aurora, Boston, Dallas, Los Angeles, New York, Seattle és Tampa (Egyesült Államok)Mind a 7 helyszín megnézéseMég 7 másik országban, 16 helyszínen
Azonosító
Állapot
Leállítva
Fázis
2/3. fázis
Résztvevők
23 fő vett részt
Kezdés
2022. jún. 3.
Befejezés
2023. nov. 24.
A vizsgálat típusa
Beavatkozással járó, 4 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • SLS-005
  • Placebo
A regiszteradat frissítve
2024. április 24.
Miért állt le
This was a business decision due to financial considerations, not based on data related to safety or therapeutic effects.

Ki vehet részt

Életkor
18 év – 75 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 24 feltétel megnézéseKevesebb

Ki vehet részt

  • Signed informed consent
  • Men and women, 18 to 75 years (inclusive) of age
  • Clinical diagnosis of SCA3 with documented genetic confirmation
  • m-SARA total score ≥ 4 at the screening visit
  • m-SARA gait component score ≥ 1 at the screening visit
  • Body Mass Index (BMI) between 18 kg/m2 and 35 kg/m2 (inclusive)
  • Stable doses of all concomitant medications for at least 30 days prior to the screening visit
  • Negative serum beta-human chorionic gonadotropin (ß-hCG) pregnancy result at the screening visit for female participants of childbearing potential
  • Willingness to comply with sexual abstinence or contraception guidelines of this study

Ki nem vehet részt

  • Current participation in another clinical trial or completed participation in an interventional trial less than 30 days prior to the screening visit (90 days for a biological treatment)
  • Prior treatment with SLS-005, any other IV trehalose formulation, or known hypersensitivity to trehalose
  • Any hereditary ataxia that is not genetically confirmed to be SCA type 3, or any type of ataxia that is acquired or secondary to another medical condition including but not limited to, alcoholism, head injury, multiple sclerosis, olivopontocerebellar atrophy, multiple system atrophy, or stroke
  • Current diagnosis and/or healthcare professional-recommended treatment (medication and/or diet) of diabetes mellitus type 1 or type 2
  • History of alcohol or drug abuse within the last 2 years
  • Chronic liver disease including Hepatitis B; Hepatitis C unless successful curative treatment is documented; human immunodeficiency virus (HIV) infection
  • Any current cardiovascular disease or abnormality on 12-lead ECG at screening that, in the investigator's opinion, is clinically significant and could be a potential safety risk to the participant
  • Any current psychiatric, neurological, or cognitive disorder that, in the investigator's opinion, may interfere with the participant's ability to provide informed consent or appropriately complete the study's safety or efficacy assessments
  • Any other medical condition or abnormal finding during screening that, in the investigator's opinion, could confound collection or interpretation of safety or efficacy data or be a potential safety risk to the participant
  • Hemoglobin A1c (HbA1c) ≥ 6.5% at the screening visit
  • Prior history of drug-induced liver injury (DILI) and/or laboratory results at screening that indicate inadequate liver function (e.g., alanine aminotransferase [ALT], aspartate aminotransferase [AST], gamma-glutamyl transferase [GGT] > 2 times the upper limit of normal [x ULN] and/or total bilirubin level > 2 x ULN)
  • Laboratory results at screening that indicate inadequate renal function (e.g., estimated creatinine clearance of < 60 mL/min calculated by the Cockcroft and Gault formula)
  • A score of 4 on any 1 of the 4 items that comprise the m-SARA
  • Pregnant or breastfeeding
  • Significant suicide risk as indicated by a "yes" response to question #4 or #5 under Suicidal Ideation in the past 6 months or any "yes" response under Suicidal Behavior in the past 3 years on the Columbia Suicide Severity Rating Scale (C-SSRS) during the screening visit

Helyszínek itt: Egyesült Államok

Még 7 másik országban, 16 helyszínen

  • UCHealth Neurosciences Center - Anschutz Medical CampusAurora, Egyesült Államok
  • Harvard Medical School - Beth Israel Deaconess Medical Center (BIDMC)Boston, Egyesült Államok
  • UT Southwestern Medical CenterDallas, Egyesült Államok
  • UCLALos Angeles, Egyesült Államok
  • Columbia University Medical CenterNew York, Egyesült Államok
  • Swedish Neuroscience Specialists - Movement DisordersSeattle, Egyesült Államok
  • University of South FloridaTampa, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

Phase 2b/3 double blind, randomized, placebo-controlled trial to assess safety and efficacy of SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion) for the treatment of adults with spinocerebellar ataxia).

A vizsgálat 4 csoportja

  • SLS-005 0.75 g/kg DoseA vizsgált kezelés

    SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion). SLS-005 will be administered as a weight-based dose of 0.75 g/kg by IV infusion once a week. For 52 weeks

    Kezelés: SLS-005

  • SLS-005 0.50 g/kg DoseA vizsgált kezelés

    SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion). SLS-005 will be administered as a weight-based dose of 0.50 g/kg by IV infusion once a week. For 52 weeks

    Kezelés: SLS-005

  • Placebo volume equivalent to a SLS-005 0.75 g/kg dose calculationPlacebo, összehasonlításként

    Placebo (sodium chloride injection, 0.9, USP) will be administered by IV infusion once a week as a weight-based volume equivalent to a SLS-005 0.75 g/kg dose. For 52 weeks

    Kezelés: Placebo

  • Placebo volume equivalent to a SLS-005 0.50 g/kg dose calculationPlacebo, összehasonlításként

    Placebo (sodium chloride injection, 0.9, USP) will be administered by IV infusion once a week as a weight-based volume equivalent to a SLS-005 0.50 g/kg dose. For 52 weeks

    Kezelés: Placebo

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Double-blind, Randomized, Placebo Controlled, Trial to Assess Safety and Efficacy of SLS-005 (Trehalose Injection, 90.5 mg/mL for Intravenous Infusion) for the Treatment of Adults With Spinocerebellar Ataxia
A regiszteradat frissítve
2024. április 24.